Case Report and Genomic Analysis of Cefiderocol-Resistant Escherichia coli Clinical Isolates

Author:

Price Travis K1ORCID,Davar Kusha2,Contreras Deisy3,Ward Kevin W1,Garner Omai B1,Simner Patricia J4,Yang Shangxin1,Chandrasekaran Sukantha1ORCID

Affiliation:

1. Department of Pathology and Laboratory Medicine, Los Angeles, CA, USA

2. Division of Infectious Disease, David Geffen School of Medicine, University of California, Los Angeles, CA, USA

3. Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA

4. Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Abstract

Abstract Objectives Cefiderocol is a novel siderophore cephalosporin with in vitro activity against multidrug-resistant (MDR), gram-negative bacteria and intrinsic structural stability to all classes of carbapenemases. We sought to identify gene variants that could affect the mechanism of action (MOA) of cefiderocol. Methods We report a case of bacteremia in a liver transplant candidate with a strain of carbapenem-resistant Escherichia coli that was found to be resistant to cefiderocol despite no prior treatment with this antimicrobial agent. Using whole-genome sequencing, we characterized the genomic content of this E coli isolate and assessed for genetic variants between related strains that were found to be cefiderocol susceptible. Results We identified several variants in genes with the potential to affect the mechanism of action of cefiderocol. Conclusions The cefiderocol resistance in the E coli isolate identified in this study is likely due to mutations in the cirA gene, an iron transporter gene.

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Reference43 articles.

1. Past and present perspectives on beta-lactamases;Bush;Antimicrob Agents Chemother,2018

2. In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM Global Surveillance Study (2012 to 2014);de Jonge;Antimicrob Agents Chemother.,2016

3. In vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing gram-negative bacilli;Vasoo;Antimicrob Agents Chemother.,2015

4. Meropenem-vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae.;Castanheira;Antimicrob Agents Chemother,2017

5. In vitro activity of cefiderocol, a siderophore cephalosporin, against gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015;Karlowsky;Int J Antimicrob Agents,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3